Elisa Fontana

19PUBLICATIONS
163CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)HaematologyCounselling psychology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|May 13, 2026
Early ctDNA Dynamics Predict Response to Mosperafenib in BRAF V600-Mutant Metastatic Colorectal Cancer.

|Apr 20, 2026
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.

|Mar 27, 2026
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors.

Maria Vieito, Elisa Fontana, Catherine H Han

|Jan 21, 2026
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results.

Ezra Y Rosen, Timothy A Yap, Elisa Fontana

|Nov 06, 2025
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.

Capucine Baldini, Loic Verlingue, Vincent Goldschmidt

|Jul 24, 2025
Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors.

Ian M Silverman, Joseph D Schonhoft, Benjamin Herzberg

Pageof 4

Frequent Collaborators

5 joint publications

Ruth Plummer

4 joint publications

Tobias Arkenau

3 joint publications

Elizabeth Lee

3 joint publications

Ezra Y Rosen